GenoMed, Inc. Announces Publication of Molecular Mechanism for Most Chronic Diseases of Adulthood
ST. LOUIS, Jan. 2 /PRNewswire-FirstCall/ -- GenoMed, Inc. (OTC Pink Sheets: GMED) ("the Company" or "GenoMed"), a St. Louis, Missouri-based medical genomics biotechnology company, announced today that a research article describing the molecular mechanism causing most chronic diseases of adulthood has been published.
The article is entitled "Is Angiotensin I-Converting Enzyme a Mechanosensor?" It proposes a simple yet elegant mechanism that unifies most of human pathology. The article claims that overactivity of angiotensin I- converting enzyme (ACE) can be associated statistically with so many different diseases only because the enzyme plays a critical function in the circulation, and the circulation controls all the tissues in the body.
Dr. David Moskowitz, GenoMed's Chairman and Chief Medical Officer, said, "The form of the enzyme which is present in our circulation is the result of a duplication of the ancestral gene, which occurred about 500 million years ago. This was the Cambrian Period, when vertebrates (animals with a backbone) first arose. In fact, there was an explosion in the number of species, called the Cambrian 'explosion.' Animals changed from an open to a closed circulation, and the pressure in the circulation went up from a few millimeters of mercury (mm Hg) to 100-200 mm Hg. The paper claims that none of this would have been possible without the duplicated form of the ACE gene. But humans and all other animals with a backbone pay a price -- we age, because the duplicated form of the gene is activated by turbulent flow with each heart beat."
Dr. Moskowitz added, "This is the missing piece of the puzzle that everyone has been looking for. Because of the treatment we've also worked out, the beauty of this discovery is that it can benefit people immediately."
The article was published in the November/December issue of Diabetes Technology and Therapeutics.
GenoMed has applied for patents on the above material, including the many disease indications for its new treatment and the new treatment itself. GenoMed is actively enrolling physicians and patients in the U.S. and abroad in its Clinical Outcomes Improvement Progam(TM), based on the Company's discoveries.
About GenoMed
GenoMed, Inc. is a medical genomics company whose mission is to improve patient outcomes by identifying the genes that cause disease. A recent St. Louis Business Journal article (http://www.stlouis.bizjournals.com/stlouis/stories/2002/05/13/story8.html ) reported that the company has applied for patents based on its finding that the ACE gene is associated with a large number of common, age-related diseases. How ACE starts these diseases is the subject of the article described here. The Company has filed patent applications on its new treatments for both human and veterinary use.
Consistent with the Company's goal to improve patient outcomes globally, GenoMed is currently working to license its treatments to physicians and healthcare systems worldwide.
For questions, please contact Krissy Fischer, tel. 1-877-GENOMED (1-877-436-6633), FAX 314-977-0042, email: kfischer@genomedics.com or visit GenoMed at www.genomedics.com.
SOURCE GenoMed, Inc.
CONTACT: Krissy Fischer of GenoMed, Inc., +1-877-GENOMED, or
+1-877-436-6633, or fax, +1-314-977-0042, or kfischer@genomedics.com/
Web site: genomedics.com |
